Galectin-3 in heart failure with preserved ejection fraction. - Wikidata - awgldk - TriplyDB

Galectin-3 in heart failure with preserved ejection fraction.

Galectin-3 in heart failure with preserved ejection fraction.

http://www.wikidata.org/entity/Q38104695

about

Patient selection in heart failure with preserved ejection fraction clinical trials State of the Art: Newer biomarkers in heart failure Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Galectin-3: a modifiable risk factor in heart failure.Candidate biomarkers in heart failure with reduced and preserved ejection fraction.Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels.Heart failure and kidney dysfunction: epidemiology, mechanisms and management.The search for efficient diagnostic and prognostic biomarkers of heart failure.New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation.Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept.Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity.Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension.Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction.Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.

P2860

Q27015845-DC29B145-FD69-4D45-AB34-41F515D8F841 Q27027899-5BF652B5-AD59-4973-BCF3-E3635E1AD486 Q31036336-BFF5DEBF-060D-4C06-A1A1-EAD6D452A2D7 Q33631289-7A671436-EC23-49F7-B7CE-DFFC576B1013 Q34375466-1778FCE3-0214-4DD8-BD03-411429619E4D Q35070734-5E16B324-42FC-49BC-8327-65D1DF82E747 Q35432573-E04D2BE3-737D-4157-AD18-5C65C9D8CEFD Q35807149-5FD9F627-16DD-4B7E-BF72-FF2228D20CBF Q38194209-6A3E67E8-763B-40A1-8E2F-1A0916635F2F Q38208784-C01CF217-0011-456F-B6A8-6535577FE132 Q38572500-955444F1-022F-411F-BC64-5480874FFB33 Q38643995-328DE492-0126-4F13-8612-9CBA3AC1C276 Q38826590-36D74B7D-C043-4FE8-9E46-AD25F101B938 Q38879246-50DBB877-718C-4375-8CDB-31B32DD6257F Q39218629-01D1483F-7DAA-486C-B92A-CE583054A20C Q41385684-F3D9B6D4-1BBF-4641-9906-5EA5B557B8B4 Q41630624-21D46067-96DE-42FA-A2FE-26EEE36835D5 Q47653100-E4E1364C-A16E-4E53-8EE8-937492C1CD75 Q48232889-3FBCF58D-9A9C-442A-8D38-C2593F49DA9D Q48617743-C05CB6E8-3356-4EB9-B81F-0964B116D6E1 Q48750580-B512A26A-7DD4-4E27-BD76-C07B1C786D6C Q52610863-9110E86C-1FBA-4EF5-B79E-2365E1137017 Q55610979-A633807D-D96E-4B29-9B8B-3B7B4DA6A7BA

P2860

Galectin-3 in heart failure with preserved ejection fraction.

http://www.wikidata.org/entity/Q38104695

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Galectin-3 in heart failure with preserved ejection fraction.

@en

type

label

Galectin-3 in heart failure with preserved ejection fraction.

@en

prefLabel

Galectin-3 in heart failure with preserved ejection fraction.

@en

P1433

Q38104695-2E6719AA-E909-42F4-9F22-D66EEDC1774D

P1476

Q38104695-AC98429F-C08A-45C1-BF32-65BC30DEA784

P2093

Q38104695-03DD81B9-5CE4-4510-B3FA-080DFC4B4120

Q38104695-1978B120-8447-4986-B407-413E331F49C4

Q38104695-78599B62-5C34-4180-B3E3-714DBE1B0F32

Q38104695-9A9538C4-E2DB-46D2-AED9-13613DB9ADA8

P2860

Q38104695-03640D02-1786-4935-89C4-78DAEC8D8D9E

Q38104695-0953EB03-6EEA-4397-8590-728F01D1691A

Q38104695-0AF5CC5A-472B-4F85-9782-4720E96A0699

Q38104695-0EA0D28F-75AC-4818-8ADF-5B49C900665A

Q38104695-1207DA24-DEFB-45F1-B641-BB55CD5ABDA2

Q38104695-14557AAE-8F4A-4335-8308-2EEF44117BFD

Q38104695-160941B8-EF17-4123-8F05-1442A18E824F

Q38104695-1BABD1F8-7AAA-4336-BDBD-606951913EB0

Q38104695-1F032D55-9323-49FB-A942-C7186AD24A19

Q38104695-21A6E83C-8222-48A2-807B-84786559374A

P304

Q38104695-C2649A7A-08A8-4C92-AF3F-3EC869D51409

P31

Q38104695-7032C4A5-0DEC-4893-AC42-304BA4C4C497

P356

Q38104695-7960E094-9EEC-4EDB-8F85-A3773DE57853

P433

Q38104695-D8BE4625-FA74-407C-A720-56A864E1B806

P478

Q38104695-3F4FD455-969E-4E47-8C9D-71794FF40D44

P50

Q38104695-605F9B32-4B9F-4D9F-ABB1-DBCF0B8EFF2B

Q38104695-8B3C3DAF-F572-4FEF-8141-87A9102770D0

P577

Q38104695-721DFAF9-3E94-4DFC-AB00-E40369CCAF1B

P5875

Q38104695-F73A82AE-9B37-45A1-8672-4B83E5EF8E02

P698

Q38104695-C7B728C8-AD91-40D1-8AEC-015909C8D835

P921

Q38104695-CADB9762-D572-416A-B12D-B458D35D38CD

P356

P1433

European Journal of Heart Failure

P1476

Galectin-3 in heart failure with preserved ejection fraction.

@en

P2093

Alan Maisel

http://www.w3.org/2001/XMLSchema#string

Frank Edelmann

http://www.w3.org/2001/XMLSchema#string

Mamas A Mamas

http://www.w3.org/2001/XMLSchema#string

Rudolf A de Boer

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology and risk profile of heart failure

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

P304

1095-1101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFT077

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Alain Cohen-Solal

P577

2013-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236643844

http://www.w3.org/2001/XMLSchema#string

P698

23650131

http://www.w3.org/2001/XMLSchema#string

P921